Currently, research of new diagnostic approaches to detect clinically significant prostate cancer is relevant because of the importance of early detection of aggressive forms of the disease, often challenging, even when using modern diagnostic tools. The aim of this review is to present the current knowledge regarding monocarboxylate transporters’ and glucose transporters’ expression as a component of glycolytic phenotype definition in prostate cancer cells.
Methods:
We searched PubMed and Scopus databases. Twenty-six articles from 2003 to 2022 were included. Literature research and selection were carried out based on the recommendations of the PRISMA statement.
Results:
The presence of “lactate shuttle” in the tumor tissue is associated with a worse prognosis. Increased expression of MCT2, MCT4, GLUT1, and down-regulation of GLUT3 are associated with prostate adenocarcinoma. MCT4 expression level correlates with the grade of tumor malignancy and disease prognosis. Up-regulation of GLUT1 and MCT4 is typical for hormone-resistant prostate cancer. Inhibition of MCT1 and MCT4 and GLUT1 in prostate cancer cells reduces their metabolic activity and growth rate, a suitable novel approach for targeted therapy.
Conclusion:
Review of the current studies showed that expression of certain MCTs and GLUTs types are associated with prostate cancer and some of them correlate with high malignancy and poor prognosis. Detection by immunohistochemistry of these transporters could represent a new diagnostic tool to identify aggressive forms of prostate cancer, and a novel therapeutic target for selective drugs.
LoebSBjurlinMANicholsonJ, et al. Overdiagnosis and overtreatment of prostate cancer. Eur Urol2014; 65(6): 1046–1055.
2.
CatalonaWJ.Prostate cancer screening. Med Clin North Am2018; 102(2): 199–214.
3.
ManciniMZazzaraMZattoniF.Stem cells, biomarkers and genetic profiling: approaching future challenges in Urology. Urologia2016; 83(1): 4–13.
4.
EliaISchmiederRChristenS, et al. Organ-specific cancer metabolism and its potential for therapy. Handb Exp Pharmacol2016; 233: 321–353.
5.
PavlidesSWhitaker-MenezesDCastello-CrosR, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle2009; 8(23): 3984–4001.
6.
HaoJChenHMadiganMC, et al. Co-expression of CD147 (EMMPRIN), CD44v3-10, MDR1 and monocarboxylate transporters is associated with prostate cancer drug resistance and progression. Br J Cancer2010; 103(7): 1008–1018.
7.
Pértega-GomesNVizcaínoJRMiranda-GonçalvesV, et al. Monocarboxylate transporter 4 (MCT4) and CD147 overexpression is associated with poor prognosis in prostate cancer. BMC Cancer2011; 11: 312.
8.
VazCVAlvesMGMarquesR, et al. Androgen-responsive and nonresponsive prostate cancer cells present a distinct glycolytic metabolism profile. Int J Biochem Cell Biol2012; 44(11): 2077–2084.
9.
SunQHuLLFuQ.MCT4 promotes cell proliferation and invasion of castration-resistant prostate cancer PC-3 cell line. EXCLI J2019; 18: 187–194.
10.
Pértega-GomesNVizcaínoJRGouveiaC, et al. Monocarboxylate transporter 2 (MCT2) as putative biomarker in prostate cancer. Prostate2013; 73(7): 763–769.
11.
ValençaIPértega-GomesNVizcainoJR, et al. Localization of MCT2 at peroxisomes is associated with malignant transformation in prostate cancer. J Cell Mol Med2015; 19(4): 723–733.
12.
FiaschiTMariniAGiannoniE, et al. Reciprocal metabolic reprogramming through lactate shuttle coordinately influences tumor-stroma interplay. Cancer Res2012; 72(19): 5130–5140.
13.
SanitàPCapulliMTetiA, et al. Tumor-stroma metabolic relationship based on lactate shuttle can sustain prostate cancer progression. BMC Cancer2014; 14(1): 154.
14.
Pértega-GomesNVizcaínoJRAttigJ, et al. A lactate shuttle system between tumour and stromal cells is associated with poor prognosis in prostate cancer. BMC Cancer2014; 14(1): 352.
15.
AndersenSSolstadØMoiL, et al. Organized metabolic crime in prostate cancer: the coexpression of MCT1 in tumor and MCT4 in stroma is an independent prognosticator for biochemical failure. Urol Oncol Semin Original Investig2015; 33(8): 338.e9–338.e17.
16.
KimHSMaskoEMPoultonSL, et al. Carbohydrate restriction and lactate transporter inhibition in a mouse xenograft model of human prostate cancer. BJU Int2012; 110(7): 1062–1069.
17.
ChoiSYXueHWuR, et al. The MCT4 gene: a novel, potential target for therapy of advanced prostate cancer. Clin Cancer Res2016; 22(11): 2721–2733.
18.
ChoiSYCEttingerSLLinD, et al. Targeting MCT4 to reduce lactic acid secretion and glycolysis for treatment of neuroendocrine prostate cancer. Cancer Med2018; 7(7): 3385–3392.
19.
MatheuxAGassiotMFromontG, et al. PXR modulates the prostate cancer cell response to afatinib by regulating the expression of the monocarboxylate transporter slc16a1. Cancers2021; 13(14): 3635.
20.
Pereira-NunesASimões-SousaSPinheiroC, et al. Targeting lactate production and efflux in prostate cancer. Biochim Biophys Acta - Mol Basis Dis2020; 1866(11): 165894.
21.
ChandlerJDWilliamsEDSlavinJL, et al. Expression and localization of GLUT1 and GLUT12 in prostate carcinoma. Cancer2003; 97(8): 2035–2042.
22.
ReinickeKSotomayorPCisternaP, et al. Cellular distribution of glut-1 and glut-5 in benign and malignant human prostate tissue. J Cell Biochem2012; 113(2): 553–562.
23.
XiaoHWangJYanW, et al. GLUT1 regulates cell glycolysis and proliferation in prostate cancer. Prostate2018; 78(2): 86–94.
24.
Gonzalez-MenendezPHeviaDAlonso-AriasR, et al. GLUT1 protects prostate cancer cells from glucose deprivation-induced oxidative stress. Redox Biol2018; 17: 112–127.
25.
WangJXuWWangB, et al. GLUT1 is an AR target contributing to tumor growth and glycolysis in castration-resistant and enzalutamide-resistant prostate cancers. Cancer Lett2020; 485: 45–55.
26.
QuWDingSCaoG, et al. miR-132 mediates a metabolic shift in prostate cancer cells by targeting glut1. FEBS Open Bio2016; 6(7): 735–741.
27.
GarlapatiCJoshiSTuragaRC, et al. Monoethanolamine-induced glucose deprivation promotes apoptosis through metabolic rewiring in prostate cancer. Theranostics2021; 11(18): 9089–9106.
28.
MeziouSRinguette GouletCHovingtonH, et al. GLUT1 expression in high-risk prostate cancer: correlation with 18F-FDG-PET/CT and clinical outcome. Prostate Cancer Prostatic Dis 20202020; 23(3): 441–448.
29.
CannistraciAHascoetPAliA, et al. MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer. Oncogene2022; 41: 1445–1455.
30.
GasinskaAJaszczynskiJRychlikU, et al. Prognostic significance of serum PSA level and telomerase, VEGF and GLUT-1 protein expression for the biochemical recurrence in prostate cancer patients after radical prostatectomy. Pathol Oncol Res2020; 26(2): 1049–1056.
31.
BakhtMKLovnickiJMTubmanJ, et al. Differential expression of glucose transporters and hexokinases in prostate cancer with a neuroendocrine gene signature: a mechanistic perspective for 18F-FDG imaging of PSMA-suppressed tumors. J Nucl Med2020; 61(6): 904–910.
32.
HoshiSMeguroSImaiH, et al. Upregulation of glucocorticoid receptor-mediated glucose transporter 4 in enzalutamide-resistant prostate cancer. Cancer Sci2021; 112(5): 1899–1910.
33.
ValençaIFerreiraARCorreiaM, et al. Prostate cancer proliferation is affected by the subcellular localization of MCT2 and accompanied by significant peroxisomal alterations. Cancers2020; 12(11): 1–15.
34.
CostelloLCFengPMilonB, et al. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis2004; 7(2): 111–117.
35.
CostelloLCFranklinRBFengP.Mitochondrial function, zinc, and intermediary metabolism relationships in normal prostate and prostate cancer. Mitochondrion2005; 5(3): 143–153.
36.
Pértega-GomesNBaltazarF.Lactate transporters in the context of prostate cancer metabolism: what do we know?Int J Mol Sci2014; 15(10): 18333–18348.
37.
FranklinRBCostelloLC.Zinc as an anti-tumor agent in prostate cancer and in other cancers. Arch Biochem Biophys2007; 463(2): 211–217.
38.
FranzMCAnderlePBürzleM, et al. Zinc transporters in prostate cancer. Mol Aspects Med2013; 34(2–3): 735–741.
39.
FraumTJLudwigDRKimEH, et al. Prostate cancer PET tracers: essentials for the urologist. Can J Urol2018; 25(4): 9371–9383.
40.
HalestrapAPMeredithD.The SLC16 gene family? From monocarboxylate transporters (MCTs) to aromatic amino acid transporters and beyond. Pflugers Arch Eur J Physiol2004; 447(5): 619–628.
41.
YoonHPhilpNJ.Genomic structure and developmental expression of the chicken nonocarboxylate transporter MCT3 gene. Exp Eye Res1998; 67(4): 417–424.
42.
YoonHFanelliAGrollmanEF, et al. Identification of a unique monocarboxylate transporter (MCT3) in retinal pigment epithelium. Biochem Biophys Res Commun1997; 234(1): 90–94.
43.
MachedaMLRogersSBestJD.Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J Cell Physiol2005; 202(3): 654–662.
